MAPT and Alzheimer disease: TSPO-PET in conjunction with tau- and/or Aβ-PET in cohorts of AD and primary tauopathy patients (i.e., progressive supranuclear palsy or corticobasal degeneration) would translate our present findings into the study of human disease.